Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001190725-17-000122
Filing Date
2017-05-11
Accepted
2017-05-11 19:10:28
Documents
1
Period of Report
2017-05-09

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT primary_doc.html 4  
1 PRIMARY DOCUMENT primary_doc.xml 4 6659
  Complete submission text file 0001190725-17-000122.txt   8078
Mailing Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Issuer) CIK: 0001576263 (see all company filings)

EIN.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O MIRATI THERAPEUTICS INC. 9393 TOWNE CENTRE DRIVE, STE 200 SAN DIEGO CA 92121
Business Address
BAUM CHARLES M (Reporting) CIK: 0001579824 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-35921 | Film No.: 17835910